Semaglutide after heart valve replacement
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether semaglutide (a medication used for diabetes and weight loss) can help people who are overweight and undergoing a TAVR procedure for a narrowed heart valve. It aims to see if it reduces complications and improves recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You are scheduled for a TAVR procedure to replace a narrowed heart valve (aortic stenosis).
- Your body mass index (BMI) is 30 or higher, OR your BMI is between 27 and 30 AND you have at least one weight-related health issue like diabetes, high blood pressure, or sleep apnea.
- You have not used any GLP-1 medications (like Ozempic, Wegovy) in the last 90 days.
- You have not had a heart attack, stroke, or certain heart procedures in the last 60 days.
- You do not have severe kidney disease (on dialysis or with very low kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether the drug semaglutide can help people with heart failure who are overweight. It aims to see if the drug improves heart function and symptoms.
This trial tests whether taking semaglutide (a once-weekly injection for weight loss) before a heart procedure called catheter ablation helps people with atrial fibrillation. It may help those with excess weight or obesity who have not used this type of medication before.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study tests whether a weekly injection of semaglutide (the same drug in Wegovy and Ozempic) can help people with atrial fibrillation lose weight and improve their heart condition. It's for people with AF who also have obesity, and may or may not plan to have a heart procedure called catheter ablation.
This trial tests if semaglutide (a weekly injection) helps people who lost less weight than expected after gastric bypass or sleeve surgery. It's for patients who had a high BMI before surgery and are in a special support program.
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.